Nektar Therapeutics (NKTR) Risk Assessment & Volatility Analysis

Comprehensive risk assessment and volatility analysis for NKTR including beta analysis, market risk, financial risk, and investment risk evaluation. Understand the potential risks and rewards of investing in NKTR stock with expert risk management insights.

Risk Assessment Summary

High price volatility

Low governance risk

Governance Risk

Overall Risk Score

5/100Low

Audit Risk

8/100Low

Board Risk

6/100Low

Compensation Risk

8/100Low

Shareholder Rights Risk

2/100Low

Market Risk

Beta (5Y Monthly)

1.28High

52-Week Change

268.42%Very High

S&P 500 52-Week Change

13.26%Very High

Short Interest Ratio

2.10Very High

Short % of Float

9.08%Very High

Volatility (Annualized)

77.65%Very High

Financial Risk

Total Debt

$167.08M

Enterprise Value

$1.22B

Profit Margins

-192.87%Very High

Earnings Growth (QoQ)

N/A

Net Income to Common

$-120736000.00

Book Value

$4.33

Risk vs Reward Analysis

Risk Factors

Beta: 1.28

Volatility: 77.65%

Short Interest: 2.10

Potential Rewards

52-Week Change: 268.42%

Earnings Growth: N/A

Profit Margin: -192.87%